Delta-Fly Pharma News

Volume change rate ranking (9:00) ~ Kringle, Coconala, etc. are ranked

* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [5/17 9:33 as of 9:33] (Last 5 Day Average Volume Comparison) Stock Code Stock Name Volume 5 Day Average Volume Volume Change Rate Stock Price Change Rate ＜7859＞ Almedio 4090100 107185.08 266.92% -0.0

Fisco JapanMay 16 20:45 ET

Turnover change rate ranking (13:00) ~ Jacks, Wako Food, etc. are ranked

* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [5/16 13:32 as of] (Last 5 Day Average Volume Comparison) Code ⇒ Stock ⇒ Volume ⇒ 5 Day Average Volume ⇒ Volume Change Ratio ⇒ Stock Price Change Ratio ＜7305＞ Shinkikou 146800 40372.5 314.41% 0.1173% ＜3393＞ Star

Fisco JapanMay 16 01:09 ET

Front market for high stop and low stop stocks

■Stop High＜1514＞Sumiseki Holdings＜1673＞WisdomTree Gin Exchange Traded Investment Trust ＜1730＞Aso Fromcleat ＜2813＞Kazuhiro Foods ＜6085＞Architects Studio Japan■Stop Yasu＜2708＞Kuze ＜2928＞RIZAP Group ＜4492＞Genetech ＜4598＞Delta-Fly PHARMA ＜6227＞AI Mecatec ＜7069＞Cyber Buzz ＜7687＞Miku Reed ＜9327＞e

Fisco JapanMay 15 23:02 ET

DELTA FLY PHARMA: Financial results presentation materials for the fiscal year ending 2024/3 20240515

JPXMay 15 02:10 ET · Announcements

DELTA FLY PHARMA: Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Unconsolidated)

JPXMay 15 02:10 ET · Announcements

Delta-Fly Pharma Sees Parent FY Loss Y1.83B

Delta-Fly Pharma Inc. also released the following forecasts: PARENT Year Ending Mar 2025 Operating Profit (Y1.82 bln) Pretax Profit (Y1.83 bln) Net Profit

Dow JonesMay 15 02:10 ET

Open H, Mitsui Chemicals, Mitsubishi Chemical G, WOWOW (15 days) (1380-4990)

*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/15 (Wed) ＜1380＞Akigawa Pasture ＜1446＞Candyle＜1447＞itbookHD ＜145A＞ELISBE＜148A＞Hatch Work ＜149A＞Shinka ＜150A＞JSH ＜1514＞Residence

Fisco JapanMay 14 17:30 ET

Volume change rate ranking (13:00) ~ Yurtech, Mirai Kogyo, etc. are ranked

* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [4/26 13:32 as of 13:32] (Last 5 Day Average Volume Comparison) Code ⇒ Stock ⇒ Volume ⇒ 5 Day Average Volume ⇒ Volume Change Ratio ⇒ Stock Price Change Ratio ＜8914＞ Area Link 279100 78254.06 286.62% 0.107% ＜1976＞ Myojo Engineering

Fisco JapanApr 26 00:59 ET

Emerging Market Stock Digest: ELTA-P rebounds drastically, Japanias is low year-to-date

Continued significant growth. It has been announced that the service “Buzz Lista,” which supports performance-guaranteed influencer marketing, has been officially released.

Fisco JapanApr 9 03:03 ET

Front market [stocks that have moved, stocks that have been created]

*Reso Education ＜4714＞ 303 Ka-Hulic implemented TOB with the aim of making it a subsidiary. *JUSTEC ＜9717＞ 1936 +226 NTT DATA TOB price continues to drop to 1940 yen. *Sakura Internet ＜3778＞ 4820 +465 went from a sense of bottoming out ahead to a move aimed at a rebound. *Nomura Micro Science ＜6254＞ has a strong buying advantage at the 5480 +49525 line split level. *Sourcenext ＜4344＞ 2

Fisco JapanApr 9 00:42 ET

4/9 [Today's Investment Strategy]

[FISCO Specially Selected Brand] [Material Brand] AFC-HD Ams Life Science ＜2927＞ 913 yen (4/8) health food contract manufacturing (OEM) manufacturer. Earnings forecasts for the first half have been revised upward. Operating profit is expected to be 1,023 million yen (up 50.8% from the same period last year). That's up about 32% from the previous forecast. The domestic healthcare business and pharmaceutical business remained steady. Also, Saikaya, which is responsible for the department store business, turned into a surplus. The full-year forecast has not been revised. Operating profit for the fiscal year ended '8/24

Fisco JapanApr 8 20:19 ET

There is also a view that it is steady and that it is falling too much in the short term

[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to develop steadily. On the US stock market yesterday 8th, the Dow average fell slightly to $38,892.80, down 11.24 dollars (-0.03%). While solid growth expectations, which received strong results from the March employment statistics, underpinned stock prices, the rise in interest rates weighed on. Buying is likely to be dominant in today's emerging markets. The main indices in the US stock market yesterday fluctuated slightly compared to last weekend and were mixed with high prices, leading to clues in the Tokyo market

Fisco JapanApr 8 19:20 ET

Check out the disclosed information for [Tomorrow's Good and Bad Materials]! (Announced on 4/8)

[Good materials] ---- ---- ■ETS Holdings [TSE S] received an order from the National Center for Global Health and Medicine for electricity receiving and substation equipment renewal and maintenance work at the National Nursing College. The construction period is from 24/4 to 25/3, and the order amount is 145 million yen. It has been factored into the earnings forecast for the fiscal year ending 24/9. ■Dawn [Tokyo Stock Exchange S]'s regular accounts for the fiscal year ending 6/2 (3Q cumulative total) landed with a 4% increase in profit, and dividends for the current fiscal year were increased by 3 yen and revised. ■Kanemi Foods [TSE S]

MinkabuApr 8 07:00 ET

Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined With Venetoclax

Following to the previous information on March 11th, 2024, we are excited to share our latest development status. We are pleased to announce the protocol for the Phase I/II clinical trial of DFP-10917 combined with

BusinesswireApr 8 07:00 ET

Delta-Fly Pharma Inc.: Abstracts Submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO Annual Meeting

Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status. A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD

BusinesswireFeb 7 06:00 ET

Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323

We are excited to share our latest development status. As presented at 2022 ASCO Annual Meeting on June 6, 2022, DFP-14323 in combination with afatinib (20 mg/day) in stage III/IV non-small cell lung cancer patients

BusinesswireFeb 2 01:15 ET

Delta-Fly Pharma Inc.: Update on the Interim Analysis Status of Phase III Study of DFP-10917 in the Patients With R/R AML

Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status. The following is the current status of the interim analysis of a Phase III study of DFP-10917 monotherapy

BusinesswireJan 30 06:00 ET

Delta-Fly Pharma Inc.: Schedule for the Interim Analysis of the Phase 3 Study of DFP-10917 in R/R AML

Following to the previous information on May 15th in 2023 (Phase 3 Study of DFP-10917 in the R/R AML Patients Shall Be Done with the 1st Interim Analysis for NDA Approval. | Business Wire), we are excited to share

BusinesswireJun 30, 2023 04:00 ET

Delta-Fly Pharma Sees Parent FY Loss Y1.32B

Delta-Fly Pharma Inc. also released the following forecasts: PARENT Year Ending Mar 2024 Operating Profit (Y1.31 bln) Pretax Profit (Y1.32 bln) Net P

Dow JonesMay 15, 2023 02:05 ET

Delta-Fly Pharma Sees Parent FY Loss Y1.15B

Delta-Fly Pharma Inc. also released the following forecasts: PARENT Year Ending Mar 2023 Revenue Y300.00 mln Operating Profit (Y1.15 bln) Pretax Prof

Dow JonesNov 14, 2022 01:18 ET